Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA.
Ann Thorac Surg. 2011 Aug;92(2):421-6; discussion 426-7. doi: 10.1016/j.athoracsur.2011.04.066.
Current guidelines suggest anticoagulation for patients with new-onset atrial fibrillation (AF). Little evidence exists for the risk/benefit ratio in postoperative general thoracic surgical patients. We analyzed new-onset AF in patients after a general thoracic operation to determine the benefit of anticoagulation on prevention of stroke and its impact on postoperative outcome.
New-onset postoperative AF developed in 759 patients (527 men, 237 women) who underwent thoracic surgical procedures between 1994 and 2009. Demographic data, clinical presentation, operative findings, and postoperative outcomes were analyzed.
The median age was 71 years (range, 31 to 92 years). We compared 228 patients anticoagulated for new-onset postoperative AF with 531 non-anticoagulated patients. The anticoagulated group had a higher incidence of male sex, pulmonary hypertension, congestive heart failure, and peripheral vascular disease. Median postoperative hospitalization was 9 days(range, 1 to 306 days) in those not anticoagulated and 11 days (range, 1 to 97 days) in those anticoagulated for AF (p=0.704). Stroke occurred in 0.56% of the non-anticoagulated patients vs 2.2% of the anticoagulated patients (p=0.057). Bleeding occurred in 22 patients (9.7%) who were anticoagulated and in 27 (5.1%) who were not (p=0.009). Anticoagulated patients had a higher incidence of at least one complication other than stroke or bleeding (43.4%) vs non-anticoagulated patients (30.9%; p=0.001). Operative mortality in anticoagulated patients was 3.1% vs 6.6% in patients not anticoagulated (p=0.057).
Anticoagulation did not lower the risk of stroke or transient ischemic attacks in postoperative general thoracic surgery patients with new-onset AF but did increase the incidence of postoperative bleeding and other complications. Patients with new-onset AF after a general thoracic surgical procedure should not be routinely anticoagulated.
目前的指南建议对新发心房颤动(AF)患者进行抗凝治疗。在接受普通胸外科手术后的患者中,关于其风险/获益比的证据很少。我们分析了普通胸外科手术后新发 AF 患者的情况,以确定抗凝治疗对预防中风的益处及其对术后结果的影响。
1994 年至 2009 年间,759 例(527 例男性,237 例女性)接受了胸外科手术,术后新发 AF。分析了人口统计学数据、临床表现、手术结果和术后结果。
中位年龄为 71 岁(范围 31 至 92 岁)。我们比较了 228 例新发术后 AF 接受抗凝治疗的患者和 531 例未抗凝治疗的患者。抗凝组男性、肺动脉高压、充血性心力衰竭和外周血管疾病的发生率较高。未抗凝组的中位术后住院时间为 9 天(范围 1 至 306 天),抗凝组为 11 天(范围 1 至 97 天)(p=0.704)。未抗凝组中风发生率为 0.56%,抗凝组为 2.2%(p=0.057)。抗凝组发生出血 22 例(9.7%),未抗凝组发生出血 27 例(5.1%)(p=0.009)。抗凝组除中风或出血外,至少有一种并发症的发生率为 43.4%,而非抗凝组为 30.9%(p=0.001)。抗凝组的手术死亡率为 3.1%,而非抗凝组为 6.6%(p=0.057)。
抗凝治疗并未降低普通胸外科手术后新发 AF 患者中风或短暂性脑缺血发作的风险,但增加了术后出血和其他并发症的发生率。普通胸外科手术后新发 AF 患者不应常规抗凝治疗。